Last reviewed · How we verify
artesunate-sulphadoxin/pyrimethamine, chloroquine
artesunate-sulphadoxin/pyrimethamine, chloroquine is a Antimalarial Small molecule drug developed by University of Oxford. It is currently in Phase 3 development for Treatment of uncomplicated malaria, Treatment of severe malaria.
Artesunate-sulphadoxin/pyrimethamine works by inhibiting the growth of malaria parasites, while chloroquine targets the parasite's digestive enzyme.
Artesunate-sulphadoxin/pyrimethamine works by inhibiting the growth of malaria parasites, while chloroquine targets the parasite's digestive enzyme. Used for Treatment of uncomplicated malaria, Treatment of severe malaria.
At a glance
| Generic name | artesunate-sulphadoxin/pyrimethamine, chloroquine |
|---|---|
| Sponsor | University of Oxford |
| Drug class | Antimalarial |
| Target | Plasmodium falciparum |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Artesunate-sulphadoxin/pyrimethamine is a combination of an artemisinin derivative and two antimalarial drugs. Artesunate inhibits the parasite's growth by generating reactive oxygen species, while sulphadoxin and pyrimethamine target the parasite's dihydrofolate reductase and dihydropteroate synthase enzymes, respectively. Chloroquine, on the other hand, targets the parasite's digestive enzyme, heme polymerase, which is essential for the parasite's survival.
Approved indications
- Treatment of uncomplicated malaria
- Treatment of severe malaria
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- artesunate-sulphadoxin/pyrimethamine, chloroquine CI brief — competitive landscape report
- artesunate-sulphadoxin/pyrimethamine, chloroquine updates RSS · CI watch RSS
- University of Oxford portfolio CI
Frequently asked questions about artesunate-sulphadoxin/pyrimethamine, chloroquine
What is artesunate-sulphadoxin/pyrimethamine, chloroquine?
How does artesunate-sulphadoxin/pyrimethamine, chloroquine work?
What is artesunate-sulphadoxin/pyrimethamine, chloroquine used for?
Who makes artesunate-sulphadoxin/pyrimethamine, chloroquine?
What drug class is artesunate-sulphadoxin/pyrimethamine, chloroquine in?
What development phase is artesunate-sulphadoxin/pyrimethamine, chloroquine in?
What are the side effects of artesunate-sulphadoxin/pyrimethamine, chloroquine?
What does artesunate-sulphadoxin/pyrimethamine, chloroquine target?
Related
- Drug class: All Antimalarial drugs
- Target: All drugs targeting Plasmodium falciparum
- Manufacturer: University of Oxford — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Treatment of uncomplicated malaria
- Indication: Drugs for Treatment of severe malaria
- Compare: artesunate-sulphadoxin/pyrimethamine, chloroquine vs similar drugs
- Pricing: artesunate-sulphadoxin/pyrimethamine, chloroquine cost, discount & access